Plasma or urine markers, including neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and N-acetyl-β-D-glucosaminidase (NAG), are promising potential biomarkers for the early detection and monitoring of AKI and CKD [3,4]. The gene discussed is LCN2; the disease is chronic kidney disease.